## Jim Young

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4461393/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Do contemporary antiretrovirals increase the risk of endâ€stage liver disease? Signals from patients starting therapy in the North American AIDS Cohort Collaboration on Research and Design. Pharmacoepidemiology and Drug Safety, 2022, 31, 214-224.	1.9	3
2	Liver Fibrosis in Human Immunodeficiency Virus (HIV)-Hepatitis C Virus (HCV) Coinfection Before and After Sustained Virologic Response: What Is the Best Noninvasive Marker for Monitoring Regression?. Clinical Infectious Diseases, 2021, 73, 468-477.	5.8	11
3	Comparing direct acting antivirals for hepatitis C using observational data – Why and how?. Pharmacology Research and Perspectives, 2020, 8, e00650.	2.4	4
4	Deep anaesthesia. Lancet, The, 2020, 396, 665-666.	13.7	1
5	The comparative effectiveness of NRTI-sparing dual regimens in emulated trials using observational data from the Swiss HIV Cohort Study. Antiviral Therapy, 2019, 24, 343-353.	1.0	4
6	Direct-Acting Antiviral Treatment Failure Among Hepatitis C and HIV–Coinfected Patients in Clinical Care. Open Forum Infectious Diseases, 2019, 6, ofz055.	0.9	10
7	Variation in hepatitis C virus treatment uptake between Canadian centres in the era of direct-acting antivirals. International Journal of Drug Policy, 2019, 65, 41-49.	3.3	16
8	High prevalence of physical inactivity among patients from the Swiss HIV Cohort Study. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2017, 29, 1056-1061.	1.2	9
9	The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver disease. BMC Infectious Diseases, 2017, 17, 45.	2.9	17
10	Dynamic Models for Estimating the Effect of HAART on CD4 in Observational Studies: Application to the Aquitaine Cohort and the Swiss HIV Cohort Study. Biometrics, 2017, 73, 294-304.	1.4	8
11	Risk Factors for Hepatitis C Virus Reinfection After Sustained Virologic Response in Patients Coinfected With HIV. Clinical Infectious Diseases, 2017, 64, 1154-1162.	5.8	64
12	Disparities in direct acting antivirals uptake in <scp>HIV</scp> â€hepatitis C coâ€infected populations in Canada. Journal of the International AIDS Society, 2017, 20, e25013.	3.0	52
13	Progression of Liver Fibrosis and Modern Combination Antiretroviral Therapy Regimens in HIV-Hepatitis C–Coinfected Persons. Clinical Infectious Diseases, 2016, 62, 242-249.	5.8	8
14	Effect of Cumulating Exposure to Abacavir on the Risk of Cardiovascular Disease Events in Patients From the Swiss HIV Cohort Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 69, 413-421.	2.1	67
15	Transient detectable viremia and the risk of viral rebound in patients from the Swiss HIV Cohort Study. BMC Infectious Diseases, 2015, 15, 382.	2.9	29
16	Favourable IFNL3 Genotypes Are Associated with Spontaneous Clearance and Are Differentially Distributed in Aboriginals in Canadian HIV-Hepatitis C Co-Infected Individuals. International Journal of Molecular Sciences, 2015, 16, 6496-6512.	4.1	5
17	Incomplete Modeling of the Effect of Antiretroviral Therapy on the Risk of Cardiovascular Events. Clinical Infectious Diseases, 2015, 61, 1206-1207.	5.8	2
18	The effects of HIV-1 subtype and ethnicity on the rate of CD4 cell count decline in patients naive to antiretroviral therapy: a Canadian-European collaborative retrospective cohort study. CMAJ Open, 2014, 2, E318-E329.	2.4	16

Jim Young

#	Article	IF	CITATIONS
19	Virus subtype, ethnicity and CD4 decline in untreated HIV infection. Future Virology, 2014, 9, 337-340.	1.8	1
20	Virologic and Immunologic Responses in Treatment-Naive Patients to Ritonavir-Boosted Atazanavir or Efavirenz With a Common Backbone. HIV Clinical Trials, 2014, 15, 92-103.	2.0	4
21	Variation between Canadian centres in the uptake of treatment for hepatitis C by patients coinfected with HIV: a prospective cohort study. CMAJ Open, 2013, 1, E106-E114.	2.4	12
22	Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir. Aids, 2012, 26, 567-575.	2.2	68
23	Re: Duc, H., Jalaludin, B. & Morgan, G. (2009). Associations between air pollution and hospital visits for cardiovascular diseases in the elderly in Sydney using Bayesian statistical methods Australian and New Zealand Journal of Statistics, 2011, 53, 257-259.	0.9	0
24	Pretreatment CD4 Cell Slope and Progression to AIDS or Death in HIV-Infected Patients Initiating Antiretroviral Therapy—The CASCADE Collaboration: A Collaboration of 23 Cohort Studies. PLoS Medicine, 2010, 7, e1000239.	8.4	54
25	Hierarchical modeling gave plausible estimates of associations between metabolic syndrome and components of antiretroviral therapy. Journal of Clinical Epidemiology, 2009, 62, 632-641.	5.0	14
26	Virological and immunological responses to efavirenz or boosted lopinavir as first-line therapy for patients with HIV. Antiviral Therapy, 2009, 14, 771-779.	1.0	9
27	Antibiotics for adults with clinically diagnosed acute rhinosinusitis: a meta-analysis of individual patient data. Lancet, The, 2008, 371, 908-914.	13.7	180
28	Antibiotics for acute rhinosinusitis $\hat{a} \in$ "Author's reply. Lancet, The, 2008, 372, 116.	13.7	0
29	Stable partnership and progression to AIDS or death in HIV infected patients receiving highly active antiretroviral therapy: Swiss HIV cohort study. BMJ: British Medical Journal, 2004, 328, 15-0.	2.3	46
30	A conventional proof of efficacy requires an intent-to-treat analysis. Journal of Clinical Epidemiology, 2004, 57, 865.	5.0	0
31	The value of a Waters' projection. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, 2003, 95, 512-513.	1.4	2
32	The clinical diagnosis of acute bacterial rhinosinusitis in general practice and its therapeutic consequences. Journal of Clinical Epidemiology, 2003, 56, 377-384.	5.0	38
33	Comparison of footprint tracking and pitfall trapping for detecting skinks. New Zealand Journal of Ecology, 0, , .	1.1	1